PTCT PTC Therapeutics Inc

$64.80

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 10/6/2025

About PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for patients with rare disorders. The company is headquartered in South Plainfield, New Jersey.

Website: https://www.ptcbio.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1070081
Address
100 CORPORATE COURT, SOUTH PLAINFIELD, NJ, US
Valuation
Market Cap
$3.74B
P/E Ratio
nan
PEG Ratio
0.81
Price to Book
1743.27
Performance
EPS
$-4.73
Dividend Yield
—
Profit Margin
-45.00%
ROE
-7740.00%
Technicals
50D MA
$50.51
200D MA
$42.12
52W High
$58.38
52W Low
$24.00
Fundamentals
Shares Outstanding
79M
Target Price
$64.64
Beta
0.58

PTCT EPS Estimates vs Actual

● Estimated
● Actual

PTCT News & Sentiment

Sep 24, 2025 • Zacks Commentary SOMEWHAT-BULLISH
BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL
FDA issues CRL to Biogen's regulatory filing seeking approval for a higher dose of SMA drug, Spinraza. The company plans prompt resubmission.
Sep 08, 2025 • Benzinga NEUTRAL
PTC Therapeutics To Challenge BioMarin's Metabolic Disorder Treatment - BioMarin Pharmaceutical ( NASDAQ:BMRN )
45% of adolescents on Palynziq cut blood phenylalanine by 50% or more from baseline. The study enrolled 55 teens; Palynziq showed better results than diet alone after 72 weeks. Get the strategy to turn September's volatility into 10x trades → On Saturday, BioMarin Pharmaceutical Inc.
Sep 05, 2025 • Motley Fool SOMEWHAT-BULLISH
Here's Why Shares in PTC Therapeutics Soared This Week
An upbeat presentation helped highlight the potential for the company's leading drug to be commercially successful.
Aug 21, 2025 • Benzinga NEUTRAL
PTC Therapeutics Stock Is Stuck In A Multi-Year Slump - PTC Therapeutics ( NASDAQ:PTCT )
PTC Therapeutics PTCT is currently in the final 18th phase of its Adhishthana cycle on the weekly chart, and the outlook remains bleak. Signals point to prolonged underperformance, with weakness likely to last through 2030. Here is how the structure unfolds under the Adhishthana framework.
Aug 19, 2025 • Benzinga NEUTRAL
PTC Therapeutics Faces FDA Rejection On Rare Disease Treatment Over Efficacy Concerns - PTC Therapeutics ( NASDAQ:PTCT )
FDA rejects PTC Therapeutics' vatiquinone, citing lack of efficacy for Friedreich's ataxia. After the complete response letter, PTC will discuss the next steps with the FDA. See what Wall Street is buying with instant access to ratings on 1,000 top stocks, including Goldman Sachs, Morgan ...
Aug 14, 2025 • Benzinga SOMEWHAT-BULLISH
Behind the Scenes of PTC Therapeutics's Latest Options Trends - PTC Therapeutics ( NASDAQ:PTCT )
High-rolling investors have positioned themselves bullish on PTC Therapeutics PTCT, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data.
Sentiment Snapshot

Average Sentiment Score:

0.120
50 articles with scored sentiment

Overall Sentiment:

Neutral

PTCT Reported Earnings

Apr 23, 2025
Mar 31, 2025 (Pre market)
0.0 Surprise
  • Reported EPS: $0.00
  • Estimate: $0.00
  • Whisper: —
  • Surprise %: 0.0%
Feb 26, 2025
Dec 31, 2024 (Post market)
0.31 Surprise
  • Reported EPS: $-0.34
  • Estimate: $-0.65
  • Whisper: —
  • Surprise %: 47.5%
Nov 07, 2024
Sep 30, 2024 (Post market)
0.05 Surprise
  • Reported EPS: $-1.39
  • Estimate: $-1.44
  • Whisper: —
  • Surprise %: 3.5%
Aug 08, 2024
Jun 30, 2024 (Post market)
-0.22 Surprise
  • Reported EPS: $-1.27
  • Estimate: $-1.05
  • Whisper: —
  • Surprise %: -20.9%
Apr 25, 2024
Mar 31, 2024 (Post market)
0.04 Surprise
  • Reported EPS: $-1.20
  • Estimate: $-1.24
  • Whisper: —
  • Surprise %: 3.2%
Feb 29, 2024
Dec 31, 2023 (Post market)
-0.74 Surprise
  • Reported EPS: $-0.24
  • Estimate: $0.50
  • Whisper: —
  • Surprise %: -148.0%
Oct 26, 2023
Sep 30, 2023 (Post market)
-0.59 Surprise
  • Reported EPS: $-1.76
  • Estimate: $-1.17
  • Whisper: —
  • Surprise %: -50.4%
Aug 03, 2023
Jun 30, 2023 (Post market)
-0.95 Surprise
  • Reported EPS: $-2.66
  • Estimate: $-1.71
  • Whisper: —
  • Surprise %: -55.6%
Apr 27, 2023
Mar 31, 2023 (Post market)
-0.36 Surprise
  • Reported EPS: $-1.88
  • Estimate: $-1.52
  • Whisper: —
  • Surprise %: -23.7%

Financials